Lodine Related Published Studies
Well-designed clinical trials related to Lodine (Etodolac)
A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. [2010.07]
Efficacy and safety of etodolac-paracetamol fixed dose combination in patients
with knee osteoarthritis flare-up: a randomized, double-blind comparative
evaluation. [2010]
A multicentric, randomized, comparative clinical trial to evaluate the efficacy
and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. [2010]
Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. [2007.03]
Etodolac versus dexamethasone effect in reduction of postoperative symptoms following surgical endodontic treatment: a double-blind study. [2006.06]
Well-designed clinical trials possibly related to Lodine (Etodolac)
The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis. [2009.01.15]
The efficacy of prostaglandin E1 derivative in patients with lumbar spinal stenosis. [2009.01.15]
COX-2 inhibition attenuates cough reflex sensitivity to inhaled capsaicin in patients with asthma. [2009]
WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. [2007.07.18]
Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. [2006.06]
[Postoperative pain management in clinics of otolaryngology] [2006]
Other research related to Lodine (Etodolac)
Comparative evaluation of efficacy and safety of etodolac and diclofenac sodium injection in patients with postoperative orthopedic pain. [2011.11]
Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. [2011.06.01]
The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety. [2011]
Randomized double-blind trial of sulindac and etodolac to eradicate aberrant
crypt foci and to prevent sporadic colorectal polyps. [2011]
Polymeric surfactant based etodolac chewable tablets: formulation and in vivo evaluation. [2010.12]
R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis. [2010.12]
Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation. [2010.09]
In-vivo gamma scintigraphic evaluation and determination of a gastro-resistant etodolac tablet in humans. [2010.07]
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. [2010.03.15]
Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation. [2010.02]
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. [2009.08.26]
Single dose oral etodolac for acute postoperative pain in adults. [2009.07.08]
Paradoxical effects of a selective cyclooxygenase-2 inhibitor, etodolac, on proliferative changes of forestomach in alloxan-induced diabetic rats. [2009.07]
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain. [2009.04]
In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac. [2009]
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. [2008.12]
The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery. [2008.10.31]
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. [2008.04]
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. [2008.04]
Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters. [2008.04]
Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. [2008.02]
Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. [2008.01]
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. [2007.12.20]
The effect of etodolac on experimental temporomandibular joint osteoarthritis in dogs. [2007.12]
In vitro and ex vivo permeation studies of etodolac from hydrophilic gels and effect of terpenes as enhancers. [2007.10]
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. [2007.09]
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. [2007.03]
Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002). [2007.02.15]
Pharmacokinetics of etodolac in the horse following oral and intravenous administration. [2007.02]
Pulmonary-renal syndrome, diffuse pulmonary hemorrhage and glomerulonephritis, associated with Wegener's granulomatosis effectively treated with early plasma exchange therapy. [2007]
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. [2006.12]
Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. [2006.11]
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. [2006.07]
Efficacy and safety of preoperative etodolac and butorphanol administration in dogs undergoing ovariohysterectomy. [2006.05]
Use of force plate analysis to assess the analgesic effects of etodolac in horses with navicular syndrome. [2006.04]
Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac. [2006]
Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. [2005.12]
Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. [2005.08.26]
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. [2005.07.15]
In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. [2005.05]
Separation of etodolac enantiomers by capillary electrophoresis. Validation and application of the chiral method to the analysis of commercial formulations. [2005.03]
Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters. [2005.02]
Other possibly related research studies
The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors. [2006.09]
Poststreptococcal reactive arthritis. [2006.07]
Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. [2006.08]
Effects of cyclooxygenase inhibition on the gastrointestinal tract. [2006.11]
High-grade slippage of the lumbar spine in a rat model of spondylolisthesis: effects of cyclooxygenase-2 inhibitor on its deformity. [2006.07.15]
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. [2006]
[Intestinal side effects of COX-2 inhibitors] [2006.03.27]
[Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors] [2006.01]
Cyclooxygenase-2 inhibitor delays fracture healing in rats. [2005.08]
Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats. [2005.08.08]
Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. [2005.04]
[Enhancement of nonsteroidal, anti-inflammatory drugs and preventive effect of antihistamines and disodium cromoglycate on wheat allergy] [2006.10]
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. [2006.07]
Anti-inflammatory effects of tretinoin (all-trans-retinoic acid) 0.1% and adapalene 0.1% in rats. [2005.09]
The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. [2005]
A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. [2005.07]
Combined administration of ethodolac, ascorbic acid and radiotherapy as adjuvant therapies in an extrathoracic desmoid tumor with gross postoperative residual disease; case report and review of the literature. [2006.07]
Microscopic periradicular surgery: perioperative predictors for postoperative clinical outcomes and quality of life assessment. [2007.03]
Systematic review of clinical trials of treatments for osteoarthritis in dogs. [2007.02.15]
Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. [2007.04.18]
Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. [2007.04]
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. [2007.08]
Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. [2007]
Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. [2007.08]
Prescription of nonsteroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopedists in Japan. [2007]
Treatment of multiple myeloma with SDX-308. [2007.09]
Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. [2007.08]
SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma. [2007.10]
Edema in a patient receiving methadone for chronic low back pain. [2007.12.15]
Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. [2008.03]
Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. [2008.02.08]
The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. [2008.05.02]
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice. [2008.03.18]
Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. [2008.09]
The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. [2008.08]
The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. [2008.08]
Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. [2008.04]
Gateways to clinical trials. [2008.06]
Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. [2009.08]
Reversible cerebral vasoconstriction syndrome: case report. [2009.08]
Systematic review of the management of canine osteoarthritis. [2009.04.04]
Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. [2009.03]
Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome. [2010.08.09]
Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. [2010.03.01]
Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. [2009.10]
Sacroiliitis and severe disability due to isotretinoin therapy. [2010.05]
Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). [2011.11.09]
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. [2011.09]
|